Century Therapeutics Reports Q2 2026 Results: $197.2M Cash Runway into 2029, CNTY-813 IND on Track for Q4
IPSC has more than doubled off its 52-week low of $0.435.
Summary
Century Therapeutics reported Q2 2026 results with $197.2M in cash, runway into 2029, and key pipeline updates: CNTY-813 IND submission on track for Q4 2026 after a successful pre-IND meeting, and CNTY-308 expected in the clinic this year.
Key Events · Earnings and Guidance · IPSC
-
Cash Runway Extended to Q1 2029
Cash, cash equivalents, and investments totaled $197.2 million as of June 30, 2026, up from $117.1 million at year-end 2025, providing runway into early 2029.
-
CNTY-813 IND Submission on Track for Q4 2026
Following a pre-IND meeting, the FDA aligned on the nonclinical data package, Phase 1 manufacturing process, and Phase 1/2 trial design for the iPSC-derived islet replacement therapy in type 1 diabetes.
-
CNTY-308 Expected in Clinic in 2026
The CD19-targeted CAR-iT cell therapy with Allo-Evasion 5.0 for B-cell-mediated autoimmune diseases remains on track to enter the clinic this year after aligning with health authorities on trial parameters.
-
Q2 2026 Net Loss of $34.6M on Reduced Spending
Net loss was $34.6 million compared to $32.5 million a year ago, with R&D expenses down 27% to $19.6 million and G&A down 26% to $5.8 million, reflecting portfolio prioritization and cost discipline.
Analysis · IPSC · Life Sciences
A cash position of $197.2 million, extending the runway into early 2029, provides a critical buffer as Century Therapeutics advances its lead T1D candidate CNTY-813 toward an IND submission in Q4 2026. The net loss widened to $34.6 million from $32.5 million a year ago, but R&D and G&A expenses declined, reflecting cost discipline. Alignment with the FDA during the pre-IND meeting on the Phase 1/2 trial design, manufacturing, and nonclinical package keeps the program on track. CNTY-308, a CD19-targeted CAR-iT for autoimmune disease, also remains on schedule to enter the clinic this year. The updated investor presentation reinforces the preclinical data and manufacturing scalability. With a market cap around $372 million, the cash position covers multiple years of development, reducing near-term financing risk, though the company remains pre-revenue and dependent on clinical execution.
At the time of this filing, IPSC was trading at $2.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $371.5M. The 52-week trading range was $0.44 to $3.04. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.